CREBBP and neoplasm: The following genomic alterations were detected: KRAS G12C, TSC2 T1181 M, EP300 R1055*, LRP1B loss exons 8–9 and loss exons 12–20, CREBBP S302 N, MED12 A1753V, PALB2 D255N, PIK3R2 E342D, STAT4 T446I, microsatellite stable disease, and tumor mutation burden of 5.59 Mut/Mb; no clearly actionable mutations were identified.